Dr. Ron Najafi, CEO, to Webcast a Clinical Development Update With Future Milestones for the Company's Four Business Units
EMERYVILLE, Calif., March 9, 2011 (GLOBE NEWSWIRE) -- Ron Najafi, PhD, Chairman and Chief Executive Officer of NovaBay Pharmaceuticals (NYSE Amex:NBY), a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, will be presenting at Roth Capital Partners' 23rd Annual Growth Stock Conference at The Ritz Carlton, Laguna Niguel in Dana Point, California. Dr. Najafi will be speaking in the Healthcare Track (Track 2) on Wednesday, March 16, 2011 at 1:30PM (PDT).
Dr. Najafi will discuss the current status of NovaBay's Aganocide ® compounds, which are novel, broad-spectrum, fast-acting antimicrobial molecules designed to mimic the body's defense against infection. When applied topically, these compounds maintain biological activities while demonstrating improved solution stability over naturally occurring antimicrobial molecules. In clinical testing in 129 patients with impetigo infections, the lead Aganocide compounds have been shown to be highly effective against bacteria, including some multi-drug resistant strains such as MRSA with 92% clinical efficacy. In preclinical testing, Aganocide compounds have also shown good activity against viruses and fungi and have the potential to deliver the same or better efficacy than antibiotics. They also address the growing problem of antibiotic resistance by employing a novel mechanism of action.The three-day Roth conference brings together executives from over 400 growth companies, including more than 135 leading biotechnology, pharmaceutical, medical devices/diagnostics and healthcare services companies. The event is designed to provide investors with a unique opportunity to gain insight into small and mid-cap growth companies across a variety of sectors, including energy, software, technology, industrials, healthcare, media, consumer and retail. The conference combines company presentations, Q&A sessions, expert panels and management one-on-one meetings to provide Roth's institutional clients with extensive interaction with senior management to gain in-depth insights into each company.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV